Finch Therapeutics Group Inc (FNCHQ)

Finch Therapeutics Group Inc is a healthcare company in the biotechnology sector whose common stock is traded on OTC Markets under the symbol FNCH.Q. The company describes itself as a clinical-stage microbiome therapeutics developer focused on orally administered biological drugs. Its pipeline includes FIN-211, a candidate being studied for gastrointestinal and behavioral symptoms associated with autism spectrum disorder, as well as FIN-524, which is being evaluated for uses that include ulcerative colitis, and FIN-525 for Crohn’s disease. Finch has also entered into collaboration and license agreements with Takeda Pharmaceutical Company Limited, along with license arrangements involving Skysong Innovations LLC, OpenBiome, Arizona State University, and the University of Minnesota. Founded in 2014 and based in Boston, Massachusetts, the company and certain affiliates filed for voluntary reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on March 22, 2026.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.